Pro-Pharmaceuticals (PRW) Announces FDA Approves IND For Use of DAVANAT
Pro-Pharmaceuticals, Inc. (Amex: PRW) announced that the FDA has granted an Investigational New Drug application for use of DAVANAT in combination with chemotherapy and biologic to treat a breast cancer patient.
Pro-Pharmaceuticals currently has two ongoing Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients. [LJ]
Pro-Pharmaceuticals currently has two ongoing Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients. [LJ]
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
